Latest revenue
$70.0K
as of 2023-09-30
Latest net income
$115.3K
as of 2023-09-30
Net margin
164.7%
as of 2023-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $25.8M
- Enterprise value
- $25.8M
- P/E (trailing)
- 0.1×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.11
- 52-wk low
- $0.01
- Beta
- —
- Shares out
- 444.5M
5-year trend
What this company does
ITEM 1. BUSINESS Company Background Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation, Pet2DAO, Inc., a Delaware corporation; and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic…
AI summary unavailable — showing raw filing excerpt
Generated from OTLC's filing dated 2026-04-15
Key risks
ITEM 1A. RISK FACTORS Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, operating results, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose part or all of your investment. Additional…
AI summary unavailable — showing raw filing excerpt
Generated from OTLC's filing dated 2026-04-15
Profitability
Operating margin
-9497.2%
Net margin
-11290.1%
Return on equity
94.9%
273.0%Return on assets
64.2%
421.7%Leverage
Debt / equity
0.48×
72.7%Debt / assets
32.3%
49.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-2.2M | -634.4% | — |
Q4 2025 2025-12-31 | — | — | $250.6M | +41809.6% | — |
Q3 2025 2025-09-30 | — | — | $-1.0M | +68.3% | — |
Q2 2025 2025-06-30 | — | — | $-20.9K | +90.1% | — |
Q1 2025 2025-03-31 | — | — | $-298.7K | +26.9% | — |
Q4 2024 2024-12-31 | — | — | $-600.9K | — | — |
Q3 2024 2024-09-30 | — | — | $-3.3M | -2965.8% | — |
Q2 2024 2024-06-30 | — | — | $-209.8K | +96.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on OTLC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$994
Insider selling
$0
Net activity
+$994
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns OTLC
No institutional holdings on file for OTLC yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once OTLC's latest filing finishes processing.